BadaryOA. (2021). Pharmacogenomics and COVID-19: Clinical implications of human genome interactions with repurposed drugs. Pharmacogenomics J, 21, 275–284.
2.
KalowW. (1962). Pharmacogenetics. Heredity and the Response to Drugs. Philadelphia, PA: W.B. Saunders Co.
3.
OhashiW, MizushimaH, and TanakaH. (2008). Economic advantage of pharmacogenomics—Clinical trials with genetic information. Stud Health Technol Inform, 136, 585–590.
4.
ÖzdemirV. (2020). Phenomics 2.0: Real-world real-time patient outcomes measured by the internet of pharmaceutical things. OMICS, 24, 119–121.
5.
OzdemirV, Suarez-KurtzG, StenneR, et al. (2009). Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of “edge effect” and cultivating an ethical bridge between omics innovations and society. OMICS, 13, 43–61.
6.
SardasS. (2010). Pharmacogenovigilance—An idea whose time has come. Curr Pharmacogen Pers Med, 8, 1–3.
7.
SardasS, BuyukAS, BecerenA. (2020). It is time to revitalize the antibiotic pipeline: Systems ecology can help. OMICS, 24, 124–128.
8.
ŞardaşS, and KendirciA. (2019). Panvigilance: Integrating biomarkers in clinical trials for systems pharmacovigilance. OMICS, 23, 134–137.
9.
Von SchombergR, and ÖzdemirV. (2020). Full throttle: COVID-19 open science to build planetary public goods. OMICS, 24, 509–511.
